SCHEMBL788784

SCHEMBL788784

C#CCc1nc2c(c(=O)[nH]c(=O)n2C)n1C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 1/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HSD17B10 Q99714 2/20 0.47
MAPK1 P28482 3/20 0.46
CYP3A4 P08684 1/20 0.46
PMP22 Q01453 1/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 2/20 0.46
CYP2C9 P11712 1/20 0.46
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DPP4 P27487 1/20 0.44
TPH1 P17752 1/20 0.44
TPH2 Q8IWU9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948261 0.81 HSD17B10 (0.55) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL515834 0.80 KDM4E (0.54) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL515910 0.80 GAA (0.53) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL315739 0.78 HSD17B10 (0.56) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL19013585 0.77 KDM4E (0.55) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL11293663 0.77 L3MBTL1 (0.57) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL8952332 0.76 ALDH1A1 (0.52) ALDH1A1NPSR1GAAL3MBTL1HSD17B10
SCHEMBL6944694 0.76 SMN1; SMN2 (0.56) ALDH1A1NPSR1TSHRGAAL3MBTL1
SCHEMBL10394507 0.75 RXFP1 (0.63) ALDH1A1NPSR1TSHRHSD17B10MAPK1
SCHEMBL11290176 0.75 KDM4E (0.59) ALDH1A1NPSR1TSHRGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 WO claimed
EP-3634421-A1 HDAC1/2 ACTIVATOR FOR PROMOTING AND/OR ACCELERATING MYELINATION AND/OR REMYELINATION Université de Fribourg (CH) 2020-04-15 EP claimed
WO-2018224650-A1 HDAC1/2 ACTIVATOR FOR PROMOTING AND/OR ACCELERATING MYELINATION AND/OR REMYELINATION UNIVERSITE DE FRIBOURG (CH) 2018-12-13 WO claimed
WO-2010065959-A1 METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY NORTHEASTERN UNIVERSITY (US) 2010-06-10 WO claimed
EP-2111231-A2 METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES NorthEastern University (US) 2009-10-28 EP claimed
EP-1765352-A4 ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR UNIV CALIFORNIA (US) 2009-07-08 EP claimed
WO-2008147482-A2 METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES NORTHEASTERN UNIVERSITY (US) 2008-12-04 WO claimed
EP-1765352-A2 ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR The Regents of the University of California (US) 2007-03-28 EP claimed
WO-2006009698-A2 ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 WO claimed
EP-1305328-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES Lyles, Mark B. (US) 2003-05-02 EP claimed
WO-2002008237-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES LYLES MARK B (US) 2002-01-31 WO claimed
WO-2024129778-A2 CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR BAFF-R AND CD19 AND METHODS AND USES THEREOF JUNO THERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
WO-2024031091-A2 CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA JUNO THERAPEUTICS, INC. (US) 2024-02-08 WO disclosed
WO-2023250400-A1 TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS JUNO THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 WO disclosed
US-5932558-A PROMOTE MIGRATION OF ENDOTHELIAL CELLS, FIBROBLASTS AND EPITHELIAL CELLS NEW YORK UNIVERSITY (US) 1999-08-03 US disclosed
EP-0814810-A4 ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART UNIV MASSACHUSETTS MEDICAL (US) 1999-06-09 EP disclosed
EP-0814810-A1 ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) 1998-01-07 EP disclosed
WO-1996028163-A1 ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) 1996-09-19 WO disclosed
WO-1994023723-A1 ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING NEW YORK UNIVERSITY (US) 1994-10-27 WO disclosed